3 unchanged sentences
By-Laws of the Company, as amended through June 29, 2020 (filed as Exhibit 3.1 to the Company’s Form 8-K dated June 30, 2020 and incorporated herein by reference).
−Removed: Fourteenth Amendment to lease dated July 17, 1990, made as of November 11, 2021 by and between Buncher Company and the Company for property located in Leetsdale, Pennsylvania (1).
−Removed: CFO Retention and Transition Agreement, dated as of November 8, 2021, by and between the Company and William P.
+Added: Second Amendment to Lease Agreement effective December 3, 2007, made as of June 17, 2022 between Mrs.
+Added: Blanca Estela Colunga Santelices and Haemonetics Mexico Manufacturing, S.
+Added: Retention and Transition Agreement, dated as of June 14, 2022, by and between the Company and Michelle L.
Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002, of Christopher A.
Simon, President and Chief Executive Officer of the Company.
−Removed: Certification pursuant to Section 302 of Sarbanes-Oxley of 2002, of William Burke, Executive Vice President, Chief Financial Officer of the Company.
+Added: Certification pursuant to Section 302 of Sarbanes-Oxley of 2002, of James C.
+Added: D'Arecca, Executive Vice President, Chief Financial Officer of the Company.
Certification Pursuant to 18 United States Code Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of Christopher A.
Simon, President and Chief Executive Officer of the Company.
−Removed: Certification Pursuant to 18 United States Code Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of William Burke, Executive Vice President, Chief Financial Officer of the Company.
−Removed: 101* The following materials from Haemonetics Corporation on Form 10-Q for the quarter ended January 1, 2022 formatted in inline Extensible Business Reporting Language (XBRL) includes:
−Removed: (i) Condensed Consolidated Statements of Income and Comprehensive Income, (ii) Condensed Consolidated Balance Sheets, (iii) Condensed Consolidated Statements of Cash Flows, and (iv) Notes to Condensed Consolidated Financial Statements.
+Added: Certification Pursuant to 18 United States Code Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of James C.
+Added: D'Arecca, Executive Vice President, Chief Financial Officer of the Company.
+Added: 101* The following materials from Haemonetics Corporation on Form 10-Q for the quarter ended July 2, 2022 formatted in inline Extensible Business Reporting Language (XBRL) includes:
+Added: (i) Condensed Consolidated Statements of Income and Comprehensive Income, (ii) Condensed Consolidated Balance Sheets, (iii) Condensed Consolidated Statement of Stockholders' Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.
104* Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).
5 unchanged sentences
HAEMONETICS CORPORATION
−Removed: February 8, 2022 By:
+Added: August 10, 2022 By:
/s/ Christopher A.
2 unchanged sentences
(Principal Executive Officer)
−Removed: February 8, 2022 By:
−Removed: /s/ William Burke
−Removed: William Burke, Executive Vice President, Chief Financial Officer
+Added: August 10, 2022 By:
+Added: D'Arecca, Executive Vice President, Chief Financial Officer
(Principal Financial Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.